ArticleArchives of dermatological research2025
Urticaria in China: incidence, prevalence, and disability-adjusted life years compared with G20 countries: findings from the Global Burden of Disease study 2021.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Burden of immune-related skin diseases worldwide, 1991-2021: insights and prediction from the Global Burden of Disease Study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Urticaria has become a major public health challenge in China, yet comprehensive national data assessments are lacking. This study analyzes the burden of urticaria in China compared to G20 countries from 1990 to 2021. Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we examined the incidence, prevalence, and disability-adjusted life years (DALYs) of urticaria by age and sex in China. Temporal trends were assessed using Average Annual Percent Change (AAPC) estimates. We also decomposed the changes in new cases, patient numbers, and urticaria burden in G20 countries and globally from 1990 to 2021. In 2021, China reported 17.30 million (95% uncertainty interval, 15.37-19.25) new cases of urticaria, 9.87 million (8.72-10.99) existing cases of urticaria, and 0.59 million (0.39-0.82) DALYs due to urticaria, ranking second among G20 countries. These metrics peaked in females under 5 years old. Age-standardized rates in China were lower than the global average and remained stable from 1990 to 2021. The under-5 age group showed the fastest growth in prevalence and DALY rates. The number of urticaria patients increased by 8.52%, with population growth contributing 19.86%, aging - 11.31%, and age-specific prevalence - 0.03%. Despite stable age-standardized rates, the absolute burden of urticaria in China has risen, particularly among females under 5 years old, highlighting the need for targeted public health interventions. Improving public emergency awareness and response is critical for urticaria patients, who may develop severe systemic diseases and fatal allergic symptoms.
Indexed as
Identifiers
40072594What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.